Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

@article{Hulin2009EfficacyOM,
  title={Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.},
  author={Cyrille Hulin and Thierry Facon and Philippe Rodon and Brigitt{\'e} P{\'e}gourie and Lotfi Benboubker and Chantal Doyen and Mamoun Dib and Gaelle Guillerm and Bruno Salles and J. -P. Eschard and Pascal Lenain and Philippe Casassus and Isabelle Aza{\"i}s and Olivier Decaux and Laurent Garderet and Claire Mathiot and Jean Eudes Fontan and Ingrid Lafon and Jean Marc Virion and Philippe Moreau},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 22},
  pages={3664-70}
}
PURPOSE Until recently, melphalan and prednisone were the standards of care in elderly patients with multiple myeloma. The addition of thalidomide to this combination demonstrated a survival benefit for patients age 65 to 75 years. This randomized, placebo-controlled, phase III trial investigated the efficacy of melphalan and prednisone plus thalidomide in… CONTINUE READING